EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Company's proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/22/23 | $50,000,000 | Series A |
GV Mubadala Capital  Polaris Capital Vivo Capital | undisclosed |
